About InVivoMAb anti-human CD44
The Hermes-1 monoclonal antibody reacts with human CD44 also known as Hermes, HCAM, and Pgp-1. CD44 is an 80-95 kDa glycoprotein that is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells. As an adhesion molecule, CD44 participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, and hematopoiesis. CD44 is a receptor for hyaluronic acid and can also interact with other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs). Additionally, CD44 is involved in tumor metastasis and targeting of CD44 by antibodies has been shown to reduce the malignant activities of various neoplasms. Interestingly, high levels of the adhesion molecule CD44 on leukemic cells are essential to generate leukemia.
InVivoMAb anti-human CD44 Specifications
Isotype | Rat IgG2a, κ |
Recommended Isotype Control(s) | InVivoMAb rat IgG2a isotype control, anti-trinitrophenol(BE0089) |
Recommended InVivoPure Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer(IP0070) |
Immunogen | Human CD44 |
Reported Applications |
|
Endotoxin |
|
Purity |
|
Formulation |
|
Sterility | 0.2 μM filtered |
Production | Purified from tissue culture supernatant in an animal free facility |
Purification | Protein G |
Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
RRID | AB_2687741 |
Molecular Weight | 150 kDa |